COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey

NCT04470648 | Completed

• 1 other identifier: C20-50
• Study Type: observational
• Target: 179
• Locations: 1 country
• Sites: 3

Brief Summary

Study of COVID-19 seroprevalence in precarious population living in shelters of Samusocial de Paris and in staff working in these centers during COVID-19 epidemic.

Conditions

SARS-COV2 Infection

Keywords

Seroprevalence; SARS-COV2; Precarious

Outcome Measures

Primary Outcomes (1)

• SARS-COV-2 seroprevalence in 3 centers for homeless and people in social distress

  Primary objective is to evaluate SARS-COV2 seroprevalence in people hosted and health care workers of 3 centers of Samusocial de Paris where COVID19 epidemics occured

  6 months

Secondary Outcomes (5)

• Morbidity rate

  6 months

• Covid-19 related death rate in the 3 centers from March to May 2020

  6 months

• Ratio of negative serology rate and positive serology rate in the 3 centers

  6 months

• Ratio of SARS-COV2 seroprevalence obtained in these centers to the estimated seroprevalence in the Ile de France region

  6 months

• kinetics of SARS-COV2 antibodies in people with initial positive serology

  10 months

Study Arms (1)

hosted in the center and HCWs at the epidemic period

people hosted in the health care or in the women center and health care workers working in one these centers during the epidemic time. People with initial positive SARS-COV2 serology will have a second blood test to mesure atibodies kinetic

Diagnostic Test: blood test for SARS-COV2 serology

Interventions

blood test for SARS-COV2 serology DIAGNOSTIC_TEST

each person who will accept to participate will have a bood test for a SARS-COV2 serology

hosted in the center and HCWs at the epidemic period

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

people hosted and workers at one these 3 centers during the epidemic time (march to may 2020)

You may qualify if:

• to have been hosted or working in one the three centers (LHSS Ridder-Plaisance or Saint Michel or Halte femmes) between march and may 2020
• to be aged 18 y or more
• to be able to give an informed consent

You may not qualify if:

• people who refuse to participate
• not being able to give an informed consent
• Person subject to a legal protection measure (safeguard of justice, curatorship or guardianship)
• Person who does not understand the information provided on how to carry out the research
• Obstacle to venous sampling

Sponsors & Collaborators

• Assistance Publique - Hôpitaux de Paris: collaborator
• Institut National de la Santé Et de la Recherche Médicale, France: lead
• Samusocial de Paris: collaborator

Study Sites (3)

Haltes pour femmes

Paris, 75004, France

Location

LHSS Saint-Michel

Paris, 75012, France

Location

LHSS Ridder-Plaisance

Paris, 75014, France

Location

Related Publications (9)

• Bernard Stoecklin S, Rolland P, Silue Y, Mailles A, Campese C, Simondon A, Mechain M, Meurice L, Nguyen M, Bassi C, Yamani E, Behillil S, Ismael S, Nguyen D, Malvy D, Lescure FX, Georges S, Lazarus C, Tabai A, Stempfelet M, Enouf V, Coignard B, Levy-Bruhl D; Investigation team. First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020. Euro Surveill. 2020 Feb;25(6):2000094. doi: 10.2807/1560-7917.ES.2020.25.6.2000094.

  PMID: 32070465 BACKGROUND

• Lescure FX, Bouadma L, Nguyen D, Parisey M, Wicky PH, Behillil S, Gaymard A, Bouscambert-Duchamp M, Donati F, Le Hingrat Q, Enouf V, Houhou-Fidouh N, Valette M, Mailles A, Lucet JC, Mentre F, Duval X, Descamps D, Malvy D, Timsit JF, Lina B, van-der-Werf S, Yazdanpanah Y. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. Lancet Infect Dis. 2020 Jun;20(6):697-706. doi: 10.1016/S1473-3099(20)30200-0. Epub 2020 Mar 27.

  PMID: 32224310 BACKGROUND

• Deslandes A, Berti V, Tandjaoui-Lambotte Y, Alloui C, Carbonnelle E, Zahar JR, Brichler S, Cohen Y. SARS-CoV-2 was already spreading in France in late December 2019. Int J Antimicrob Agents. 2020 Jun;55(6):106006. doi: 10.1016/j.ijantimicag.2020.106006. Epub 2020 May 3.

  PMID: 32371096 BACKGROUND

• Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W; China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727-733. doi: 10.1056/NEJMoa2001017. Epub 2020 Jan 24.

  PMID: 31978945 BACKGROUND

• Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020. Euro Surveill. 2020 Feb;25(5):2000062. doi: 10.2807/1560-7917.ES.2020.25.5.2000062.

  PMID: 32046819 BACKGROUND

• Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W, Chen C, Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JT, Gao GF, Cowling BJ, Yang B, Leung GM, Feng Z. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020 Mar 26;382(13):1199-1207. doi: 10.1056/NEJMoa2001316. Epub 2020 Jan 29.

  PMID: 31995857 BACKGROUND

• Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.

  PMID: 32109013 BACKGROUND

• Baggett TP, Keyes H, Sporn N, Gaeta JM. Prevalence of SARS-CoV-2 Infection in Residents of a Large Homeless Shelter in Boston. JAMA. 2020 Jun 2;323(21):2191-2192. doi: 10.1001/jama.2020.6887.

  PMID: 32338732 BACKGROUND

• Husain M, Rachline A, Cousien A, Rolland S, Rouzaud C, Ferre VM, Gomez MV, Le Teurnier M, Wicky-Thisse M, Descamps D, Yazdanpanah Y, Charpentier C, Pasquet-Cadre A. Impact of the COVID-19 pandemic on the homeless: results from a retrospective closed cohort in France (March-May 2020). Clin Microbiol Infect. 2021 Oct;27(10):1520.e1-1520.e5. doi: 10.1016/j.cmi.2021.05.039. Epub 2021 Jun 7.

  PMID: 34111590 RESULT

Biospecimen

Retention: SAMPLES WITHOUT DNA

blood for serology testing

MeSH Terms

Conditions

COVID-19

Interventions

Hematologic Tests

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Investigative Techniques

Study Officials

• Yazdan Yazdanpanah, MD PHD

  Assistance Publique - Hôpitaux de Paris

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 12, 2020
• First Posted: July 14, 2020
• Study Start: July 22, 2020
• Primary Completion: April 8, 2021
• Study Completion: August 22, 2021
• Last Updated: January 26, 2026

Record last verified: 2023-02

Locations

FR (3)